Compare OTH & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTH | DXR |
|---|---|---|
| Founded | 2012 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.2M | 71.4M |
| IPO Year | N/A | 1995 |
| Metric | OTH | DXR |
|---|---|---|
| Price | $2.45 | $10.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.0K | 12.7K |
| Earning Date | 12-15-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | $600.18 | ★ $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.95 | $7.10 |
| 52 Week High | $3.75 | $14.76 |
| Indicator | OTH | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 25.51 |
| Support Level | $2.03 | $10.00 |
| Resistance Level | $2.72 | $10.49 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 66.67 | 10.78 |
Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Boat Sales and Azure Funding. Boat Sales includes Specializing in the buying, selling, and wholesaling of yachts and boats, having a boat dealership created to run Yellow Fin sales in Miami; and Azure Funding includes a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.